Luis “Louie” Sapien, 69, of Las Cruces, New Mexico, passed away on December 12, 2025, at Mountain View Regional Medical Center. Luis was born in El Paso, Texas to Serafin “Fito” and Maria Angel Gloria ...

The Sapien M3 transcatheter mitral valve replacement system won FDA approval -- making it the first on the market to utilize a transseptal approach -- for the treatment of symptomatic ...

Edwards Lifesciences (EW) announced on Tuesday that the U.S. Food and Drug Administration approved its SAPIEN M3 transcatheter mitral valve replacement (TMVR) system for patients with mitral ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the agency’s first in this type of implant that takes a potentially safer route ...

Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach to receive U.S. Food and ...

South Korean IC design house Sapien Semiconductor is emerging as a disruptor in the global smart glasses supply chain, after reports that it will supply display backplanes for Meta's next-generation ...

Natalia Garcia-Lee works in many media, including jewelry, but in her solo exhibition in the generously proportioned gallery at Miami-Dade College, the artist, born in Madrid and who lives part of the ...

Scientists at UCLA have developed an "off-the-shelf" cell-based immunotherapy that was able to track down and kill pancreatic cancer cells even after they had spread to other organs. In a mouse study, ...

SAN FRANCISCO -- For selected patients with mitral regurgitation (MR), the Sapien M3 device delivered highly promising 1-year outcomes for the desperate field of transcatheter mitral valve replacement ...

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...